Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok T. S. K., Wu Y., Kudaba I., Kowalski D. M., Cho B. C., TURNA Z. H., ...More

LANCET, vol.393, no.10183, pp.1819-1830, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 393 Issue: 10183
  • Publication Date: 2019
  • Doi Number: 10.1016/s0140-6736(18)32409-7
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1819-1830
  • Ankara University Affiliated: No

Abstract

Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.